Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
Clinical trial NCT07491159 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07491159
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-01
- Primary completion
- 2026-06-30
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.